Published in TB and Outbreaks Week, January 9th, 2001
The researchers monitored 34 pulmonary tuberculosis patients for changes in cytokine as well as T helper cell status during the nine-month study. Patients were evaluated prior to study initiation and then every three months after they began anti-tuberculosis therapy.
"Before the anti-TB chemotherapy the prevalent cytokine pattern was Th1, with a sensible increase of interleukin (IL)-2, soluble IL-2 receptor (sIL-2R), IL-12, gamma...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.